2023
Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer
Check D, Jackson B, Reeder-Hayes K, Dinan M, Faherty E, Kwong J, Mehta S, Spees L, Wheeler S, Wilson L, Lam C. Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer. Breast Cancer Research And Treatment 2023, 203: 329-338. PMID: 37875669, DOI: 10.1007/s10549-023-07142-4.Peer-Reviewed Original ResearchConceptsHER2-low breast cancerBreast cancerHealthcare utilizationOutcomes of patientsRetrospective cohort studyStage IV diseaseStage IV patientsMetastatic breast cancerNew treatment guidelinesRate of hospitalizationBreast cancer patientsClinical characteristicsCohort studyHazard ratioIV patientsOverall cohortPositive diseaseTreatment guidelinesIHC 0Utilization outcomesTreatment optionsCancer patientsSurvival differencesPatientsStage IV
2022
Treatment patterns and health care resource use of patients with metastatic breast cancer with HER2-low expression: A cancer registry-linked insurance claims study.
Check D, Jackson B, Spees L, Dinan M, Kwong J, Mehta S, Wheeler S, Wilson L, Faherty E, Reeder-Hayes K, Lam C. Treatment patterns and health care resource use of patients with metastatic breast cancer with HER2-low expression: A cancer registry-linked insurance claims study. Journal Of Clinical Oncology 2022, 40: 399-399. DOI: 10.1200/jco.2022.40.28_suppl.399.Peer-Reviewed Original ResearchMetastatic breast cancerAnti-HER2 therapyHER2-low expressionMBC patientsEmergency departmentIHC 0Endocrine monotherapyEndocrine therapyTreatment patternsInfusion visitsCDK4/6 inhibitorsHER2 expressionBreast cancerDe novo metastatic breast cancerRetrospective population-based cohort studyNovo metastatic breast cancerBreast cancer-specific mortalityCancer-specific mortality ratesPopulation-based cohort studyHealth care resource useState cancer registry dataHormone receptorsCancer-specific mortalityHealthcare resource utilizationHormone receptor status